1. Hammes HP, Du X, Edelstein Det al.Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Med2003;9:244–9.
2.
2. Brownlee M.The pathobiology of diabetic complications: a unifying mechanism. Diabetes2005;54:1615–25.
3.
3. Herve C, Beyne P, Letterom P, Delacoux EComparison of erythrocyte transketolase activity with thiamine phosphate ester levels in chronic alcoholic patients. Clin Chim Acta1995;234:91–100.
4.
4. Pepersack T, Garbusinski J, Robberecht J, Beyer I, Willems D, Fuss MClinical relevance of thiamine status amongst hospitalized elderly patients. Gerontology1999;45:96–101.
5.
5. Shimon I, Almong S, Vered Zet al.Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med1995;98:485–90.
6.
6. Saito N, Kimura M, Kuchiba A, Itokawa YBlood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol (Tokyo)1987;33:421–30.
7.
7. Vuilleumier JP, Keller HE, Rettenmaier R, Hunziker FClinical chemical methods for the routine assessment of the vitamin status in human populations. Part II: The water-soluble vitamins B1, B2 and B6. InternatJ Vit Nutr Res1983;53:359–70.
8.
8. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes2003;52:2110–20.
9.
9. Stracke H, Hammes HP, Werkmann Det al.Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes2001;109:330–6.
10.
10. Haupt E, Ledermann H, Kopcke WBenfotiamine in the treatment of diabetic polyneuropathy - three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther2005;43:71–7. Erratum in: Int J Clin Pharmacol Ther 2005;43:304.